Neuroendocrine differentiation in prostate cancer (Q36537698)

14 August 2017

1 reference

title

Neuroendocrine differentiation in prostate cancer (English)

1 reference

14 August 2017

1 reference

M Hammad Ather

2

0 references

author name string

Amir H Shariff

series ordinal

1

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

68

1 reference

14 August 2017

issue

1

1 reference

14 August 2017

page(s)

2-8

1 reference

14 August 2017

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Early detection of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker"

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Neuro-endocrine cells--a new prognostic parameter in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Neurogenic origin of human prostate endocrine cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Do neuroendocrine cells in human prostate cancer express androgen receptor?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Neuroendocrine differentiation in human prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Carcinoid TumorsAn analysis of 2837 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Effect of prostatic neuropeptides on invasion and migration of PC-3 prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Prostate cancer. Primary hormonal treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Neoadjuvant Hormonal Deprivation in Patients with Locally Advanced Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Androgen receptor gene mutations in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

The biology of hormone refractory prostate cancer. Why does it develop?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Circulating neuroendocrine markers in patients with prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Modulation of Prostate Carcinoma Cell Growth and Apoptosis by Chromogranin A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

Neuroendocrine serum tumour markers in hormone-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.002

10.1016/J.UROLOGY.2006.02.002

7 January 2021

Identifiers

DOI

1 reference

14 August 2017

1 reference